Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.
Nussbaum DP, Martz CA, Waters AM, Barrera A, Liu A, Rutter JC, Cerda-Smith CG, Stewart AE, Wu C, Cakir M, Levandowski CB, Kantrowitz DE, McCall SJ, Pierobon M, Petricoin EF 3rd, Joshua Smith J, Reddy TE, Der CJ, Taatjes DJ, Wood KC.
Nussbaum DP, et al. Among authors: wu c.
NPJ Precis Oncol. 2024 May 31;8(1):124. doi: 10.1038/s41698-024-00615-9.
NPJ Precis Oncol. 2024.
PMID: 38822082
Free PMC article.